指南与共识妇科肿瘤

ESMO关于卵巢癌同源重组缺陷预测性生物标志物检测与PARP抑制剂获益的建议

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
指南 / 共识 · Ann Oncol · 2020-09-28

ESMO转化研究与精准医学工作组通过系统综述方法,定义了HRD检测术语、梳理了现有HRD检测的生物学依据与证据水平,并给出其在高级别浆液性卵巢癌临床管理中的效用建议。文章指出BRCA突变检测及两种纳入基因组不稳定性的商业化检测可识别PARP抑制剂获益幅度不同的亚组,但现有检测缺乏阴性预测价值,急需更好的生物标志物。

要点

  • BRCA突变检测和两种纳入基因组不稳定性的商业化检测可用于识别PARP抑制剂获益幅度不同的HGSC亚组。
  • 现有HRD检测缺乏阴性预测价值,不能可靠识别从PARP抑制剂无获益的患者亚组。
  • 现有检测未能充分反映HRD表型的复杂性和动态性,急需更好的生物标志物。

核心结论

  • 现有HRD检测有助于预测PARP抑制剂的可能获益幅度,但急需更好的生物标志物以识别当前同源重组功能状态并分层HGSC管理。

研究设计与样本

  • ESMO转化研究与精准医学工作组启动协作项目,纳入系统综述方法,旨在定义HRD检测术语、概述现有HRD检测的生物学依据与证据水平、并给出临床效用建议。

主要发现

  • 广泛的修复基因、基因组瘢痕、突变特征和功能检测均与HRD病史相关。
  • 卵巢癌中HRD检测的临床有效性最好以PARP抑制剂获益而非生物学HRD状态本身来评估。
  • 临床试验证据支持使用BRCA突变检测和两种纳入基因组不稳定性的商业化检测来识别PARP抑制剂获益幅度不同的HGSC亚组,但不同临床情景下存在差异。
  • 现有检测缺乏阴性预测价值,且未能充分反映HRD表型的复杂性和动态性。

关键数值与推荐

  • 临床试验证据支持BRCA突变检测和两种纳入基因组不稳定性的商业化检测用于识别PARP抑制剂获益幅度不同的HGSC亚组。
  • 这些检测可用于指导治疗选择和排程。

临床怎么用

  • HRD检测可用于预测PARP抑制剂的可能获益幅度,辅助治疗选择和排程。
  • 不应依赖现有检测的阴性结果排除PARP抑制剂获益可能。

局限性

  • 现有检测缺乏阴性预测价值。
  • 现有检测未能充分反映HRD表型的复杂性和动态性。
  • 多数研究中现有检测未能一致识别从PARP抑制剂无获益的患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an opportunity to optimise PARPi use in HGSC but methodologies are diverse and clinical application remains controversial. MATERIALS AND METHODS: To define best practice for HRD testing in HGSC the ESMO Translational Research and Precision Medicine Working Group launched a collaborative project that incorporated a systematic review approach. The main aims were to (i) define the term 'HRD test'; (ii) provide an overview of the biological rationale and the level of evidence supporting currently available HRD tests; (iii) provide recommendations on the clinical utility of HRD tests in clinical management of HGSC. RESULTS: A broad range of repair genes, genomic scars, mutational signatures and functional assays are associated with a history of HRD. Currently, the clinical validity of HRD tests in ovarian cancer is best assessed, not in terms of biological HRD status per se, but in terms of PARPi benefit. Clinical trials evidence supports the use of BRCA mutation testing and two commercially available assays that also incorporate genomic instability for identifying subgroups of HGSCs that derive different magnitudes of benefit from PARPi therapy, albeit with some variation by clinical scenario. These tests can be used to inform treatment selection and scheduling but their use is limited by a failure to consistently identify a subgroup of patients who derive no benefit from PARPis in most studies. Existing tests lack negative predictive value and inadequately address the complex and dynamic nature of the HRD phenotype. CONCLUSIONS: Currently available HRD tests are useful for predicting likely magnitude of benefit from PARPis but better biomarkers are urgently needed to better identify current homologous recombination proficiency status and stratify HGSC management.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020. PMID: 33004253. doi:10.1016/j.annonc.2020.08.2102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。